This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Melodiol Global Health マネジメント

マネジメント基準チェック /14

Melodiol Global Healthの CEO はWill Layで、 Jan2022年に任命され、の在任期間は 2.75年です。の年間総報酬はA$ 894.88Kで、 46%給与と54%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.006%を直接所有しており、その価値はA$ 70.81 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と2.8年です。

主要情報

Will Lay

最高経営責任者

AU$894.9k

報酬総額

CEO給与比率	46.0%
CEO在任期間	2.8yrs
CEOの所有権	0.006%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	2.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Melodiol Global Health の収益と比較して、Will Lay の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	AU$895k	AU$412k	-AU$36m
Jun 30 2023	n/a	n/a	-AU$54m
Mar 31 2023	n/a	n/a	-AU$43m
Dec 31 2022	AU$408k	AU$389k	-AU$22m

報酬と市場: Willの総報酬 ($USD 588.46K ) は、 Australian市場 ($USD 304.34K ) の同規模の企業の平均を上回っています。

報酬と収益: Willの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Will Lay

2.8yrs

在職期間

AU$894,875

報酬

Mr. William Lay, also known as Will, B.Com (Hons.) is CEO & MD of Health House International Limited from 2024. He serves as Group Chief Executive Officer, Managing Director and Director at Melodiol Global...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Christopher Grundy	Chief Financial Officer	6.9yrs	AU$628.01k	0.00014% A$ 1.6
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Gian Trepp	Commercial & Marketing Director	5.8yrs	データなし	データなし
Mitchel Fleming	Managing Director of Halucenex	no data	データなし	データなし
Brett Ayers	Managing Director of Impactive	no data	データなし	データなし
Winton Willesee	Joint Company Secretary	6yrs	データなし	データなし
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	データなし	データなし

4.3yrs

平均在職期間

経験豊富な経営陣: ME1の経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	データなし	データなし
Walter Von Wartburg	Member of Scientific Advisory Board	5.8yrs	データなし	データなし
Bruce Linton	Independent Non-Executive Director	2.8yrs	AU$82.72k	0.0019% A$ 22.0
Isaac Kobrin	Member of Scientific Advisory Board	no data	データなし	データなし
Felix Gutzwiller	Member of Scientific Advisory Board	7.6yrs	データなし	データなし
Peter Hatfull	Non-Executive Director	1.9yrs	AU$83.26k	データなし
Ben Quirin	Non-Executive Director	2yrs	AU$82.80k	データなし

2.8yrs

平均在職期間

73.5yo

平均年齢

経験豊富なボード: ME1の取締役会は経験豊富ではない ( 2.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

This company listing is no longer active

Melodiol Global Health マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Less than half of directors are independent

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.24

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14